Sangamo Biosciences (SGMO) Receives a Rating Update from a Top Analyst

By Carrie Williams

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Sangamo Biosciences (SGMOResearch Report) today. The company’s shares closed last Monday at $11.66.

According to, Baral is a top 100 analyst with an average return of 24.6% and a 52.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.

Sangamo Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $13.50.

See today’s analyst top recommended stocks >>

Based on Sangamo Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $27.31 million. In comparison, last year the company had a GAAP net loss of $12.84 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.